Advertisement
Screener

LENZ THERAPEUTICS, INC. (LENZ) Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount

2.1 / 5 stars · 15/35 Roast Me

LENZ THERAPEUTICS, INC. Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount

LENZ THERAPEUTICS, INC. (LENZ) reported Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount · last filed 2026-08-11

  • LENZ THERAPEUTICS, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2026-06-30 was $0.00.
  • LENZ THERAPEUTICS, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2026-03-31 was $0.00.
  • LENZ THERAPEUTICS, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2025-09-30 was $0.00.
  • LENZ THERAPEUTICS, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2025-06-30 was $0.00.
  • LENZ THERAPEUTICS, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2024 was $0.00.
Period endEquity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 3 monthEquity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 6 monthEquity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 9 monthEquity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 12 month
2026-06-30$0.00
10-Q · filed 2026-08-11
$0.00
10-Q · filed 2026-08-11
2026-03-31$0.00
10-Q · filed 2026-05-11
2025-12-31$400.00K
10-Q · filed 2026-08-11
2025-09-30$0.00
10-Q · filed 2025-11-05
$0.00
10-Q · filed 2025-11-05
2025-06-30$0.00
10-Q · filed 2026-08-11
$0.00
10-Q · filed 2026-08-11
2025-03-31$0.00
10-Q · filed 2026-05-11
2024-12-31$0.00
10-K · filed 2026-03-24
2024-09-30$0.00
10-Q · filed 2024-11-06
$0.00
10-Q · filed 2024-11-06
2024-06-30$0.00
10-Q · filed 2025-07-30
$0.00
10-Q · filed 2025-07-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48